Precigen, Inc. (PGEN) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.27: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.4/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.32; Below-average business quality.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting... Read more
Sell if holding. Engine safety override at $4.27: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.4/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.32; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 3.4/10, high confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Precigen, Inc.
Latest news
- Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11 — benzinga May 14, 2026 positive
- HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11 — benzinga May 14, 2026 positive
- Why Cisco Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket — benzinga May 14, 2026 positive
- Transcript: Precigen Q1 2026 Earnings Conference Call — benzinga May 13, 2026 neutral
- Precigen Q1 EPS $(0.02), Inline, Sales $23.252M Beat $20.800M Estimate — benzinga May 13, 2026 positive
Generated 2026-05-20T22:01:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.27: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.4/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Elevated put/call ratio: 1.32; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $3.97. Score 3.4/10, high confidence.
Take-profit target: $9.35 (+119.0% upside). Prior stop was $3.97. Stop-loss: $3.97.
Quality below floor (2.2 < 4.0).
Precigen, Inc. trades at a P/E of N/A (forward -18.9). TrendMatrix value score: 0.0/10. Verdict: Sell.
9 analysts cover PGEN with a consensus score of 4.0/5. Average price target: $11.
What does Precigen, Inc. do?Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using...
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.